CLDI

Business Context and Reporting Period

Company: Calidi Biotherapeutics, Inc. (CLDI)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2025
Business Overview: A clinical-stage biotechnology company developing genetic medicines and proprietary genetically-engineered oncolytic viruses (RedTail, SuperNova, NeuroNova platforms). The company has no approved products and generates no revenue from product sales.
Corporate Actions: On August 4, 2025, the company effected a 1-for-12 reverse stock split. All share and per-share data in this filing have been retrospectively restated to reflect this split.

Key Financial Metrics

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses decreased by 14% to $10.7 million for the six months ended June 30, 2025, compared to $12.5 million in the prior year period. This was driven primarily by a 25% reduction in General and Administrative (G&A) expenses due to lower legal fees, salaries, and insurance costs.
• Net Loss: Net loss attributable to common stockholders improved by 27% to $10.7 million (six months 2025) from $14.7 million (six months 2024), largely due to reduced operating expenses and lower interest costs.
• Debt Reduction: The company significantly reduced its debt load, settling $1.8 million in term notes and bridge loans during the six-month period. Total debt carrying value decreased from $3.8 million at year-end 2024 to $1.4 million at June 30, 2025.
• Financing Activity: The company raised approximately $10.1 million in gross proceeds during the first half of 2025 through public offerings and a registered direct offering, partially offset by debt repayments.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern: Management has concluded there is substantial doubt about the company's ability to continue as a going concern for at least 12 months from the date of issuance. Cash on hand ($5.4 million) is insufficient to fund operations for the next year without additional financing.
• Outlook: The company expects to continue incurring significant operating losses as it advances clinical trials for its product candidates (CLD-101, CLD-201, CLD-401). Future funding will be required through equity or debt offerings, which may result in dilution.
• Recent Developments:
  • Executive Changes: Allan Camaisa resigned as CEO and Chairman in April 2025; Eric Poma was appointed CEO. A separation agreement with Mr. Camaisa involves $500,000 in separation pay.
  • Warrant Inducement: In July 2025 (subsequent to period end), the company executed a warrant inducement offer raising $4.6 million in gross proceeds.
  • Fast Track Designation: In July 2025, the FDA granted Fast Track Designation to CLD-201 for the treatment of soft tissue sarcoma.
• Risks: Key risks include the inability to raise additional capital, failure of clinical trials, and ongoing litigation (including a securities fraud complaint filed in October 2024 and employment-related disputes).

Investor Verification Checklist

• Liquidity Runway: Verify the company's immediate plans to raise capital given the "substantial doubt" going concern warning and cash balance of only $5.4 million.
• Debt Obligations: Review the terms of the remaining $1.4 million in debt, specifically the $0.8 million in related party term notes and the $0.6 million promissory note, to understand upcoming maturity dates and interest burdens.
• Dilution Impact: Assess the impact of the 1-for-12 reverse stock split and the significant number of outstanding warrants (1.4 million shares) on future share price and ownership dilution.
• Legal Contingencies: Monitor the status of the securities fraud lawsuit filed by Mr. Yian Zeng and the employment litigation involving former officers, as outcomes could result in material liabilities.
• Related Party Transactions: Scrutinize the $0.8 million in related party term notes and the $500,000 separation agreement with the former CEO for terms and repayment schedules.